Sign In
Buy MLTX
$18.27
+0.400 (+2.24%)
At Close: Jun 03, 2026
FDA Aligns With MoonLake On Lead Drug Submission Plans, Stock Soars
11:44am, Monday, 11'th May 2026
MoonLake Immunotherapeutics (NASDAQ:MLTX) shares are up during Monday's trading session, trading higher as the company is reporting positive outcomes from its final pre-BLA meeting with the FDA regard
MoonLake Clears A Key Regulatory Hurdle, And Shares Rocket
11:08am, Monday, 11'th May 2026
Shares of MoonLake Immunotherapeutics bounded higher Monday after the biotech said it met with the Food and Drug Administration in April.
ZUG, Switzerland, May 10, 2026 – MoonLake Immunotherapeutics (NASDAQ: MLTX) (“MoonLake” or the “Company”), a clinical-stage biotechnology company focused on creating next-level therapies for
The CEO of MoonLake Immunotherapeutics Dumped Shares Worth $2.8 Million. Should Investors Avoid the Stock?
10:17am, Saturday, 18'th Apr 2026
CEO Jorge Santos da Silva sold 150,000 shares for a transaction value of approximately ~$2.75 million, based on a weighted average sale price of $18.35 per share. The sale represented 4.9% of Mr.
Da Silva Jorge Santos Sells 98,127 Shares of MoonLake Immunotherapeutics (NASDAQ:MLTX) Stock
04:05am, Thursday, 16'th Apr 2026
MoonLake Immunotherapeutics (NASDAQ: MLTX - Get Free Report) CEO Da Silva Jorge Santos sold 98,127 shares of the firm's stock in a transaction on Friday, April 10th. The shares were sold at an average
MoonLake Immunotherapeutics (NASDAQ:MLTX) Trading Down 6% – Should You Sell?
04:11am, Sunday, 12'th Apr 2026
MoonLake Immunotherapeutics (NASDAQ: MLTX - Get Free Report)'s share price traded down 6% during mid-day trading on Friday. The company traded as low as $18.36 and last traded at $18.2540. 326,345 sha
Biotech Fund BVF Trims MoonLake Stake, Sells $63M in Shares
02:07pm, Tuesday, 07'th Apr 2026
BVF sold 3,750,000 shares for a transaction value of approximately $62.96 million on April 2, 2026. The sale represented 78.30% of BVF's direct holdings, reducing direct ownership to 1,039,238 shares.
ZUG, Switzerland, March 28, 2026 – MoonLake Immunotherapeutics (NASDAQ: MLTX) (MoonLake or the Company), a clinical-stage biotechnology company focused on creating next-level therapies for inflammat
MoonLake Immunotherapeutics (NASDAQ:MLTX) Shares Gap Up After Analyst Upgrade
01:32am, Friday, 20'th Mar 2026
MoonLake Immunotherapeutics (NASDAQ: MLTX - Get Free Report) gapped up prior to trading on Thursday after Rothschild and Co Redburn upgraded the stock from a neutral rating to a buy rating. The stock
This Fund Bought $28 Million of a Beaten-Down Immunotherapy Stock Last Quarter. What Should Long-Term Investors Know?
07:36pm, Monday, 16'th Mar 2026
Cormorant Asset Management increased its MoonLake Immunotherapeutics position by 2,361,260 shares in the fourth quarter; the estimated trade value is $27.86 million based on average quarterly prices.
Avoro Capital Advisors LLC Cuts Stock Position in MoonLake Immunotherapeutics $MLTX
03:07am, Saturday, 14'th Mar 2026
Avoro Capital Advisors LLC lessened its holdings in shares of MoonLake Immunotherapeutics (NASDAQ: MLTX) by 51.8% in the undefined quarter, according to the company in its most recent 13F filing with
MoonLake Immunotherapeutics (NASDAQ:MLTX) Receives Consensus Recommendation of “Hold” from Analysts
02:50am, Friday, 13'th Mar 2026
MoonLake Immunotherapeutics (NASDAQ: MLTX - Get Free Report) has been assigned a consensus recommendation of "Hold" from the sixteen analysts that are presently covering the firm, MarketBeat Ratings r
Uniqure To Rally Around 92%? Here Are 10 Top Analyst Forecasts For Wednesday
08:19am, Wednesday, 11'th Mar 2026
Top Wall Street analysts changed their outlook on top names. See all changes on analyst ratings page.
MoonLake: Downgrade To Buy As Sonelokimab Still Has A BLA Shot On Goal
01:50pm, Tuesday, 24'th Feb 2026
MoonLake Immunotherapeutics is downgraded from Strong Buy to Buy following a mixed phase 3 outcome for sonelokimab in hidradenitis suppurativa [HS]. Despite VELA-2's primary endpoint miss, the FDA's p
MoonLake Immunotherapeutics Investor Day: HS BLA on Track, axSpA Phase 2 Data Highlights Imaging Wins
01:16am, Tuesday, 24'th Feb 2026
MoonLake Immunotherapeutics (NASDAQ: MLTX) used its Investor Day presentation to outline updates across its clinical portfolio for sonelokimab (SLK), a tri-specific nanobody designed to inhibit IL-17A
